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RESULTS: A total of 54,341 RA patients met the study inclusion criteria; mean 
age 59 years, 67% female. Of these patients, a total of 1033 (1.9%) died in 2011. 
Age and sex-specific mortality rates were: male/age 18-35 (0/532;0.0%); 
female/age 18-35 (1/2391;0.0%%); male/age 36-55 (16/4889 0.3%); female/age 36-55 
(27/13462;0.2%); male/age 56-75 (191/9455;2.0%); female/age 56-75 
(190/15891;1.2%); male/age 76+ (271/3128;8.5%); female/age 76+ (337/4593;7.3%). 
CONCLUSIONS: This is the first study to describe annual mortality in a large 
prevalence-based sample of U.S. RA patients. Additional analyses to examine 
risk factors and suspected causes of mortality are warranted.  
 
PMS15  
EVIDENCE ON SAFETY OF METAL-ON-METAL HIP RESURFACING 
ARTHROPLASTY  
Sehatzadeh S, Levin L 
Health Quality Ontario, Toronto, ON, Canada  
OBJECTIVES: Metal-on-metal hip resurfacing arthroplasty (MOM HRA) is an 
alternative to total hip arthroplasty in young patients. There are multiple reports 
indicating higher rate of revision for MOM HRA and health regulators are 
currently scrutinizing failure rates and safety of these implants. The revision 
rates of implants licensed in Canada were compared with the benchmark set by 
the National Institute of Clinical Excellence (NICE), i.e., a revision rate of 10% or 
less at 10 years. METHODS: Studies published from January 1, 2009 to February 
13, 2012 were included. The literature was examined to identify articles 
discussing the biological effects of metal implants. RESULTS: The revision rates 
for MOM HRA with BHR, ConservePlus, and Cormet implants met NICE criteria. 
Revision rate for ReCap implant was 2% at a mean follow-up of 2.9 years. Two 
studies reported revision rates of 3.7% and 11% for Durum implant at a mean 
follow-up of 5 years. The ASR implant had a revision rate of 10.9% at 5 years. In 
addition to implant design, several factors including selection of patients and 
skills of the surgeons in proper positioning of the implant that helps to reduce 
rate of wear contributed to the success of the procedure. The consensus among 
orthopedic surgeons is that the ideal patients for MOM HRA are young male 
patients with end-stage hip osteoarthritis, good bone quality, and proper 
anatomy around the affected joint. There are reports of high levels of metal ions 
in the blood and urine of patients with these implants. Production of metal 
debris due to friction between the 2 components may result in inflammation in 
the joint or development of a soft tissue mass leading to implant failure. 
CONCLUSIONS: MOM HRA can be beneficial for appropriately selected patients, 
provided the surgeon has the surgical skills required for performing this 
procedure.  
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Prior to 2012, the reimbursement criteria for osteoporosis medications has been 
criticized for its strict BMD indication and 6-month coverage period in Korea. The 
cost estimate of expanding coverage to clinically recommended level was 130 
billion KRW. OBJECTIVES: To suggest a better estimate of budget impacts for 
osteoporosis drug therapy in Korea METHODS: A 5-year semi-annual Markov 
model focusing on the fracture-preventing effects of osteoporosis medications 
was constructed. Fracture-preventing effects of osteoporosis drugs were 
extracted from previous systematic reviews and the HIRA’s national health 
insurance claims database from 2006 to 2008 was used to estimate the 
probabilities and costs for modeling. Mortality rate at each stage was estimated 
from the literature and the Statistics Korea. The Korean National Health and 
Nutrition Examination Survey data and Korean FRAX tool were utilized to 
calculate the population at each stage. The scenarios of reimbursement criteria 
expansion were composed of BMD T-score, coverage period, and including high-
fracture-risk patients with osteopenia. RESULTS: Reimbursement coverage 
expansion is expected to increase budget input, but the increase gradually 
decrease over time. If the reimbursement criteria is expanded to T-score≤-2.5, 
coverage period increased to 1 year, but excluding high-fracture-risk osteopenia, 
then about 450 billion KRW is required for osteoporosis drug acquisition for 5 
years along with 120 billion KRW saving for fracture treatment costs compared to 
the existing criteria. Considering both expansion costs and fracture costs, the 
reduction in fracture costs partially offsets the expanded coverage of 
osteoporosis drugs. In summary, 87 billion KRW was estimated for the first year 
budget impact and it gradually decreases to about 50 billion KRW in the fifth 
year. CONCLUSIONS: This budget impact analysis considering both increase in 
osteoporosis drug cost and saved fracture cost shows the total health insurance 
budget impact is lower than the previously suggested amount.  
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OBJECTIVES: To estimate annual cost per treated patient for etanercept, 
adalimumab, infliximab, abatacept, rituximab, golimumab, certolizumab, and 
ustekinumab in rheumatoid arthritis (RA), psoriasis, psoriatic arthritis, and 
ankylosing spondylitis in a US claims population. METHODS: MarketScan 
Commercial Database was used to identify patients (18-63 years) with ≥1 claim 
for a biologic of interest between January 1, 2008 and December 31, 2010 
preceded by ≥6-months of enrollment and a diagnosis of RA, psoriasis, psoriatic 
arthritis, or ankylosing spondylitis. The first drug claim meeting these criteria 
defined the index date and biologic. “Continuing” patients had ≥1 claim for the 
same biologic before their index date, “New” patients did not. Patients were 
required to be continuously enrolled for 1-year following the index claim. 
Patients with Crohn’s disease, or ulcerative colitis pre-index were excluded since 
not all biologics are approved for these indications. Mean monthly dose and total 
dose of other biologics after discontinuation of their index biologic was 
calculated for the 12-months after index. Wholesale acquisition costs and the 
Medicare Physician Fee Schedule were applied to the mean monthly dose and 
related drug administration to calculate cost per treated patient. RESULTS: A 
total of 69,349 patients were included, 92.3% received etanercept (32,298), 
adalimumab (20,582), or infliximab (11,157). Patient characteristics were similar 
across groups; mean age 47.8 years (SD 10.2), 63% female. Mean annual cost per 
treated patient pooled across indications was $20,508 etanercept, $21,179 
adalimumab, and $23,446 infliximab. Cost per treated patient in RA (55% of 
patients) ranged from $18,888 abatacept to $22,158 infliximab and in psoriasis, 
(20% of patients), from $21,034 adalimumab to $31,478 ustekinumab. 
CONCLUSIONS: Based on drug utilization from this US managed care population, 
of agents approved for all indications, etanercept had the lowest cost per treated 
patient across all indications. In RA, abatacept had the lowest cost, whereas 
infliximab had the highest.  
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OBJECTIVES: To estimate annual biologic cost per treated patient in rheumatoid 
arthritis (RA), plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis 
using drug utilization from US managed care. METHODS: The IMS LifeLink 
Health Plan Claims Database was used to identify adults (18-63 years) with a 
claim for etanercept, adalimumab, infliximab, abatacept, rituximab, golimumab, 
certolizumab, or ustekinumab between January 1, 2008 and December 31, 2010 
preceded by ≥180-days of enrollment. Patients had to have a qualifying diagnosis 
between 180 days before and 30 days after index and be enrolled for ≥360 days 
post-index. The first biologic claim meeting these criteria defined the index date. 
Patients with pre-index Crohn’s disease, ulcerative colitis, non-Hodgkins 
lymphoma, or chronic lymphocytic lymphoma were excluded. Annual cost per 
treated patient equaled total dose for the index biologic and biologics taken after 
discontinuation of the index biologic multiplied by October 2012 WAC, plus 
number of administrations multiplied by the 2012 Medicare Physician Fee 
Schedule costs. RESULTS: Of 35,525 included patients; 92.7% received etanercept 
(n=16,704), adalimumab (n=10,154), or infliximab (n=6,056). Most patients (63%) 
were female, mean age 48.9 years and treated for RA (56%). Pooled across 
indications, cost per treated patient for agents approved for all indications was 
$20,284 for etanercept, $20,010 for adalimumab, and $22,795 for infliximab. Cost 
per treated patient in RA was $19,251 for etanercept, $20,387 for adalimumab, 
$21,585 for infliximab. The range in other agents was from $16,286 for 
golimumab (n=120) to $19,710 for certolizumab (n=101). In psoriasis, cost per 
treated patient ranged from $20,261 for adalimumab (n=1,874), to $34,951for 
ustekinumab (n=116). The costs in other groups were similar to those in RA. 
CONCLUSIONS: Of agents approved for all indications, infliximab, which is 
infused, had higher costs than adalimumab or etanercept which are self-
injected. Although some new agents had lower costs in RA, sample size for these 
agents was limited.  
 
PMS19  
INPATIENT HOSPITAL COSTS AND LENGTH OF STAY FOR THE TREATMENT OF 
OSTEOPOROSIS FRACTURES IN CHINA  
Li J1, Burge RT2, Ye WW3, Yang Y4, Du F5, Ma Y1, Zhang J1 
1China Health Insurance Research Association, Beijing, China, 2Eli Lilly and Company, 
Indianapolis, IN, USA, 3Lilly Suzhou Pharmaceutical Co., Ltd. Shanghai Branch, Shanghai, China, 
4Eli Lilly Suzhou Pharmaceutical Co. Ltd. Shanghai Branch, Shanghai, China, 5Beijing Brainpower 
Pharma Consulting Co. Ltd., Beijing, China  
OBJECTIVES: The prevalence of osteoporosis fractures is anticipated to increase 
rapidly due to China's aging population. However, nationally representative data 
on inpatient hospital costs and length of stay (LOS) for osteoporosis fractures are 
lacking. The study was to estimate hospitalization costs, LOS, costs/day, and the 
co-pay burden among patients with osteoporosis fractures in China. METHODS: 
Data were extracted from the China Health Insurance Research Association 
claim database which includes a nationwide, cross-sectional sampling of 
inpatients from 2008-2010. The descriptive analysis included inpatients (≥50 
years) who had discharge diagnosis of fracture (vertebral, hip, non-
vertebral/non-hip(NVNH), or multiple fractures) and either had a diagnosis of 
pathological osteoporosis or osteoporosis drug treatment. Total medical costs 
and LOS were calculated and compared by Wilcoxon test within subgroups. 
RESULTS: The analysis included 830 patients (female:77.4%, mean age:73.4 
years). The medians of overall LOS and total costs were 19 days and 18587.0 RMB. 
Patients≥70 years (n=581) had greater LOS and costs than patients <70 years 
(median: 19 vs. 17 days, p<0.01; 21527.6 vs. 14748.6 RMB, p<0.01). Cost/day in 2008 
was 801.9±861.9 RMB, which increased by 74.3% in 2009 and 89.2% in 2010. Hip 
fractures had the longest LOS (22 days) and highest cost (32593.8 RMB); and were 
significantly greater than NVNH fracture (18 days, p<0.01; 17185.0 RMB, p<0.01). 
Reimbursement of costs by basic health insurance in 2008, 2009 and 2010 was 
51.8%, 54.7%, and 60.8%, respectively; while the corresponding patient co-pay 
